A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region

Viswanathan S Rose N Masita A et al . Multiple sclerosis in Malaysia: Demographics, clinical features, and neuroimaging characteristics. Mult Scler Int 2013; 2013: e614716.

Vijayasingham L Viswanathan S Zain MN et al . Improvements and success in the management of multiple sclerosis: Fifteen years of experience from a single-centre public hospital. In PACTRIMS 2017; 23–25 November 2017; Ho Chi Minh City, Vietnam. Mult Scler J 2018; 24: 368–423.

Ministry of Health Malaysia. Clinical practice guidelines: Management of multiple sclerosis. Ministry of Health Malaysia, 2016, http://www.moh.gov.my/penerbitan/CPG/CPG%20Management%20of%20Multiple%20Sclerosis.compressed.pdf

Viswanathan S Arip M Mustafa N et al . The frequency of anti-aquaporin-4 Ig G antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in Malaysia, https://www.hindawi.com/journals/msi/2014/568254/ (2014, accessed 20 November 2017).

Vijayasingham L Viswanathan S. Access to disease-modifying treatment in Malaysia: A multilevel and multi-actor perspective. Mult Scler J 2018; 24(3): 392–393.

Vijayasingham L Jogulu U Allotey P. Challenges for accessing and financing high-cost medicines in multipayer systems: Case studies of multiple sclerosis in Malaysia. Crit Public Health. Epub ahead of print 23 May 2017. DOI: 10.1080/09581596.2017.1403011.

Mao Z Álvarez-Gonzalez C De Trane S et al . Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? Mult Scler J Exp Transl Clin. Epub ahead of print 26 June 2018. DOI: 10.1177/2055217318783767.